Thermo Fisher
Scientific exploring greener pastures
Thermo Fisher Scientific
is now venturing into a business strategy to include not just
faster but also user-friendly products in addition to an
aggressive acquisition spree.
—Koos Van Der
Steujit, vice president and general manager, Thermo Fisher Scientific
![](/IMG/900/45900/koosvan.gif)
For the past one year ThermoFisher Scientific (TFS) looks at newer
turfs to enhance its growth—both globally and within Indian
shores. The Massachusetts-based company clocked a revenue of
$10 million this fiscal, with its Indian subsidiary itself
achieving a double digit growth of around 40 percent and clocking
fiscal sales of Rs 394.6 crore from its life sciences focused business.
It was the number one Biosupplier in the Biospectrum-ABLE survey for
fiscal 2007-08.
The company has revolutionized its product offering. A simple case in
point being that 15 years ago the best mass spectrometry would take one
year to analyze a protein and today this has been reduced to a mere 30
seconds!
TFS is also now looking at spreading its capabilities to newer
geographies like India and China. Though a country like India accounts
for just one percent of its total revenue pie, the region can certainly
not be ignored. Projecting stupendous growth, its business in China
today is thrice that of India. Its overall growth can be attributed to
the spree of acquisitions and collaborations within a span of a year,
opening up of new manufacturing facilities and inking major deals and
programs with government institutions.
—Amit Chopra,
managing director, Laboratory products, Thermo Fisher Scientific
![](/IMG/901/45901/amitchoera.gif)
Acquisitions and
collaborations—the global stratagem
The year 2008 was marked by acquisitions and collaborations for TFS.
The underlying point behind the stratagem is not just doubling revenue
but to broaden its geographical distribution and simultaneously
widening its product portfolio offering. This business strategy has
worked in favor of the company. TFS completed two acquisitions in
India. While Qualigens Fine Chemicals, supplier of laboratory
chemicals, was acquired from GlaxoSmithKline (GSK) in 2007, and
Chemito, a supplier of analytical instruments for life sciences and
environmental monitoring applications, was acquired in 2008. And this
in a way pushed the company’s annual revenues to double (Rs
395.6 crore) as compared to the previous fiscal figure (Rs 246 crore).
“Thermo was also looking for a good equipped team. This
acquisition will be of great help for our chemicals, diagnostics and
glass ware business,” said Dr G Ramakrishnan, managing
director of Thermo Electron LLS, India Ltd. In addition,
Chemito manufactures its own analytical instruments, including gas
chromatography, atomic absorption and UV-Vis spectroscopy.
Chemito’s analytical technologies and environment
instrumentation divisions have annual revenues of approximately $10
million and will be integrated into Thermo Fisher’s
analytical technologies Segment. Dr G Ramakrishnan also added that
“Chemito gives us a manufacturing base in Nasik and
strengthens our analytical instrument base in India. Chemito has
developed a good training center and Thermo will be able to strengthen
its training base and give hands on training to its
customers.”
On the global platform, the company has moved at a breathtaking speed
and within a span of one month, the company has completed one
acquisition and one collaboration. With these acquisitions, TFS got a
foothold in anatomical pathology with the London-based, Raymond A Lamb.
Clocking annual revenue of $9 million, Raymond A Lamb will be
integrated with the analytical technologies segment. TFS had then
collaborated with biotech giant Genentech for the development of novel
small interfacing therapeutics for Genentech.
Speaking exclusively to Biospectrum, Global CEO and President of TFS,
Marijn Dekkers said, “RNA interference (RNAi), which is used
for silencing bad genes, is one of the technologies
that I am excited about. We are accelerating all our technology
platforms towards this end.” In December 2008, Thermo Fisher
also entered into a program, to assist food testing and government labs
for the analysis of melamine in food products from China (especially in
milk products) in the wake of an alert from the United States Food and
Drug Administration (USFDA) on adulterated milk products. TFS will
provide the complete testing solution right from sample preparation,
instrumentation and consumable along with food experts in the
technology.
India-China, hotbeds for
growth
There has also been a paradigm shift in geographical
preferences. The global economy in the coming years will see the
dominance of the yellow and the brown men. Recognizing the mammoth
business opportunities these regions offer in the future, TFS has
already started its ground work. While commenting on this Koos Van Der
Steujit, vice president and general manager, TFS, India, said,
“A lot of growth will be seen in India and China in the next
few years. We aim to double our growth in these regions. TFS is already
exploring opportunities in these nations and we will see a lot of
actions here.”
TFS has taken significant steps over the past few years to expand its
footprint in India, beginning with the opening of a state-of-the-art
demonstration laboratory in Mumbai that offers customers with its range
of laboratory solutions. The company has also added sales and
manufacturing facilities to support growing markets, including
biopharma services and biospecimen storage, life sciences research and
environmental analysis. Thermo Fisher India now has more than 600
employees and 20 facilities, including the new full-service clinical
packaging and distribution facility in Ahmedabad.
Clinical trials pursuit
in India
Despite grabbing a minor share of the pie, India continues to
be the center of attraction for the company. With India becoming the
hub for R&D, the CROs and MNCs are flourishing in the country,
TFS does not want to miss this opportunity. Its clinical trials
business has been operative globally. However, it is only recently that
the endeavor has been introduced in the Asia-Pacific countries.
“These countries have a great potential that is why TFS is
looking at setting up its clinical trials business here,”
said Koos Van Der Steujit.
Recently TFS announced the official opening of its new $17
million facility in Ahmedabad to support the growing demand
for biopharma services. The 150,000 square feet facility will focus on
packaging, global distribution and logistics management of tightly
regulated pharmaceutical samples to patients participating in clinical
trials across the globe. It complements the company’s
existing clinical services operations in the US, Europe and
Asia. “India continues to be a major market of
focus for us as we expand our capabilities to support clinical research
and development. Our customers are eager to outsource their clinical
trials management to partners who know how to work within changing
regional and global clinical trial regulations. Now, with the added
capacity available with us, we will be able to bring a higher level of
technology, quality and expertise to facilitate clinical trials that
serve the needs of both multi-national and local pharmaceutical
companies,” said Marijn Dekkers
Stem cell research
ThermoFisher Scientific is concentrating on providing
technology to high growth potential segments that include protein
research and stem cell research. After the Thermo-Fisher
merger, in the beginning of January 2008, TFS launched its stem cell
excellence program, which will cater to the entire spectrum of stem
cell research.
“Thermo Fisher Scientific has a continuous focus on providing
integrated work flow solutions to some of the most promising areas in
scientific research, such as stem cell research, IVF and cell
culture,” said Amit Chopra, managing director, Laboratory
products, Thermo Fisher Scientific. The line of instruments cater to
the needs like collection and preparation, differentiation,
characterization, storage and transportation. The expanded stem cell
excellence portfolio now includes Thermo Scientific HyClone Advance
STEM reagents, kits and stem cell lines, as well as the Thermo
Scientific Dharmacon Accell siRNA reagent for gene silencing and Nunc
cell culture inserts for cell-based assays. A breakthrough
gene-silencing tool, the Dharmacon Accell small-interfering RNA (siRNA)
product line, has also been used within the Thermo Scientific Stem Cell
Excellence program. The Accell siRNA enables uptake by stem cells and
other difficult cell types without the use of viral or lipid-based
delivery systems, which can be toxic to cells.
There is no looking back for the company now. Despite the
recession and the credit crunch, TFS is optimistic that it will
continue on its growth path but at the same time on a cautious note.
“We will be cautious but at the same time invest in
high growth areas,” confirmed Koos Van Der Steujit.
N Suresh and Nayantara
Som in Mumbai